AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06716021
Drug: Etripamil
RxNorm normalized name: etripamil
DrugBank: Etripamil (DB12605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The formulation of etripamil is for IN administration and will consist of etripamil, water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg with an optional second dose of 70 mg 10 minutes after the first dose if symptoms persist.
Trial: NCT06723197
Drug: vonoprazan+amoxicillin
RxNorm normalized name: vonoprazan
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug combinations for dual regimens：vonoprazan+amoxicillin
Trial: NCT06704334
Drug: Huperzine A injection
RxNorm normalized name: huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular
Trial: NCT06728033
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous tramadol at a dose of 2 mg/kg
Trial: NCT04905810
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04905810
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06729853
Drug: SAP-001
RxNorm normalized name: HURA CREPITANS SAP
DrugBank: AP-001 (DB18511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral dose of SAP-001
Trial: NCT04905810
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05339217
Drug: Telitacicept
RxNorm normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.
Trial: NCT05339217
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
Trial: NCT06222268
Drug: Cannabidiol (CBD) only
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabis consisting of 2.5mg CBD and 0mg Delta-9-tetrahydrocannabinol (THC) is delivered through a vaporizer.
Trial: NCT06222268
Drug: Delta-9-tetrahydrocannabinol (THC) only
DrugBank: Cannabinol (DB14737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis containing 2.5mg THC and 0mg CBD is delivered through a vaporizer.
Trial: NCT05805436
Drug: Polyethylene Glycol 3350
RxNorm normalized name: Polyethylene Glycol 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the intervention arm will take polyethylene glycol 3350 for three days before robotic urologic surgery. Patients in the control arm will not.
Trial: NCT04603651
Drug: Bamlanivimab
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV).
Trial: NCT06281561
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Female patients undergoing hysteroscopy receive nasal spray with dexmedetomidine before anesthesia
Trial: NCT05297669
Drug: Felbinac Trometamol Injection
RxNorm normalized name: felbinac
DrugBank: Felbinac (DB07477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours.
Trial: NCT04850144
Drug: Tiotropium Bromide Monohydrate
RxNorm normalized name: tiotropium bromide monohydrate
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Easyhaler 10 µg/dose Product variant D
Trial: NCT04850144
Drug: Tiotropium Bromide Monohydrate
RxNorm normalized name: tiotropium bromide monohydrate
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Easyhaler 10 µg/dose Product variant E
Trial: NCT04850144
Drug: Tiotropium Bromide Monohydrate
RxNorm normalized name: tiotropium bromide monohydrate
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Easyhaler 10 µg/dose Product variant F
Trial: NCT04850144
Drug: Tiotropium Bromide Monohydrate
RxNorm normalized name: tiotropium bromide monohydrate
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Easyhaler 10 µg/dose Product variant G
Trial: NCT04850144
Drug: Tiotropium Bromide Monohydrate
RxNorm normalized name: tiotropium bromide monohydrate
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium Easyhaler 10 µg/dose Product variant H
Trial: NCT04850144
Drug: Tiotropium Bromide Monohydrate
RxNorm normalized name: tiotropium bromide monohydrate
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiriva 18 µg/capsule inhaled via Handihaler
Trial: NCT04850144
Drug: Tiotropium Easyhaler with oral activated charcoal
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The charcoal suspension will be administered orally with Tiotropium Easyhaler 10 µg/dose Product variant F
Trial: NCT06327581
Drug: Lactic Acid
RxNorm normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will be treated with MN combined with lactic acid solution 1%. Lactic acid solution 88% concentration PH (6.84), diluted with distilled water to have a final concentration of 1%
Trial: NCT06327581
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will be treated with MN combined with triamcinolone acetonide injectable suspension (Epirelefan®, 40mg/ ml, Eipico, Egypt) (10 mg/ml) will be used in a dose of 0.1 ml/cm2 area
Trial: NCT06327581
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will be treated with MN combined with normal saline 0.9%
Trial: NCT00000694
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000694
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000694
Drug: Sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05110027
Drug: Enpatoran
RxNorm normalized name: Enpatoran
DrugBank: Enpatoran (DB16501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of enpatoran tablet on Day 1
Trial: NCT05110027
Drug: [14C]enpatoran microtracer
DrugBank: Enpatoran (DB16501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of non-labeled enpatoran solution spiked with microtracer of \[14C\]enpatoran on Day 1 of Period 1.
Trial: NCT05110027
Drug: [14C]enpatoran microdose
DrugBank: Enpatoran (DB16501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intravenous \[14C\]enpatoran microdose administered at 1.5 hours after the oral dose of enpatoran on Day 1 of Period 2.
Trial: NCT04860154
Drug: Hematoporphyrin
RxNorm normalized name: hematoporphyrin
DrugBank: Hemoporfin (DB16183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with negative skin test of hematoporphyrin Injection (3.0-5.0mg/Kg plus saline 250 mL intravenous drip, the drip was completed within 1 hour) and keep patients away from the light. The first PDT therapy was performed 24 hours after infusion of hematoporphyrin injection by ERCP. The biliary tumor necrosis was observed and the biliary tract was cleaned up 24 hours later and then PDT therapy showed again if necessary. Multiple plastic stents or bald metal stents will be placed. Follow up regularly after the procedure, PDT therapy would be given again in 3 months.
Trial: NCT04963764
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive oral amoxicillin for a standard course (10 days)
Trial: NCT06373523
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10mg daily will be given to the treatment arm.Eligible subjects will be followed up until week 28, and will undergo clinical, anthropometric and laboratory assessments (including liver function test and lipid profile) at baseline, week 14 and week 28. They will undergo LSM and CAP By Transient Elastography at baseline, week 14 and week 28, and MRI-PDFF at baseline and week 28. The primary outcome will be a difference in change of liver fat content (measured by MRI-PDFF) at week 28 from baseline between the two groups.
Trial: NCT05963139
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: US guided IPACK block will be performed with 10/15/20 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0,25 bupivacaine.
Trial: NCT05963139
Drug: Morphine Sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this group,adductor block will be performed with 15 ml %0,25 bupivacaine using a 22 gauge 10 mm block needle and patients will be postoperatively administered patient controlled analgesia with morphine.
Trial: NCT04799925
Drug: Febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: uric acid lowering agent. dose: 80 mg once daily. duration: for 6 months
Trial: NCT05467189
Drug: Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As part of routine treatment.
Trial: NCT05147844
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab: 240mg, iv. Q3W for 1 year or until disease progression/intolerable toxicity~Radiotherapy:~Newly diagnosed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 70 Gy, pGTVnd 99Gy, pCTV1, 60 Gy, pCTV2, 54 Gy, 33 times, completed in 7 weeks.~Relapsed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 60Gy, pGTVnd 60Gy, 20-25 times, completed in 4-5 weeks.~Newly diagnosed and relapsed patients: SBRT for oligometastatic lesions, pGTV 25-40 Gy, 3-5 times, completed in 1-2 weeks.
Trial: NCT04645667
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be enrolled into this group if they receive tacrolimus per standard of care. This is an observational study and no interventions will be made.
Trial: NCT05979415
Drug: Apomorphine Cartridge
RxNorm normalized name: apomorphine Cartridge
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Staccato Cartridge
Trial: NCT04650074
Drug: LIDOCAINE 20 mg
RxNorm normalized name: lidocaine 20 MG/ML
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute.
Trial: NCT06218160
Drug: Hydromorphone combined with ropivacaine
RxNorm normalized name: HYDROMORPHONE/ROPIVACAINE
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg hydromorphone was added to 0.375% ropivacaine for a total of 30ml to perform quadrat block
Trial: NCT06218160
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A mixture of 0.375% ropivacaine for a total of 30ml was used for quadrate block
Trial: NCT04650074
Drug: LIDOCAINE 20 mg + KETAMINE 20 mg
RxNorm normalized name: lidocaine 20 MG/ML
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute.
Trial: NCT04650074
Drug: LIDOCAINE 20 mg + KETAMINE 40 mg
RxNorm normalized name: lidocaine 40 MG/ML
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute
Trial: NCT05781386
Drug: SIM1811-03 or in combination with Sintilimab injectiont
RxNorm normalized name: Thiazides, combinations with psycholeptics and/or analgesics
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumor.~Sintilimab is an IgG4 humanized monoclonal antibody against programmed cell death protein 1 (PD-1)
Trial: NCT05705843
Drug: Intraosseous Vancomycin Injection
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • IO vancomycin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the OR after sterile prep and draping has occurred prior to skin incision (500mg in 150mL NS).
Trial: NCT05705843
Drug: Intravenous Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Vancomycin will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL NS).
Trial: NCT04918862
Drug: Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 210 patients were enrolled, divided into two groups \[Granisetron 1 mg: 105 patients received 1mg granisetron, Granisetron 3 mg: 105 patients received 3mg granisetron\]. The two groups were compared in demographic characteristics (age, gender, weight, and height), hemodynamic parameters (MAP and HR), and duration of surgery
Trial: NCT05617430
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg IV d1, Q3W
Trial: NCT05617430
Drug: Bevacizumab Biosimilar IBI305
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7.5mg/kg IV d1, Q3W
Trial: NCT06270706
Drug: PLN-101095
RxNorm normalized name: PLN-74809
DrugBank: PLN-74809 (DB16515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLN-101095
Trial: NCT06270706
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab
Trial: NCT03678428
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.
Trial: NCT03678428
Drug: Oxaliplatin HAI
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
Trial: NCT03678428
Drug: Floxuridine
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
Trial: NCT03678428
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 2400mg/m2 CIV in 46h on Day 1 and 15.
Trial: NCT03678428
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/m2 IV over 3 hours on Day1 and 15.
Trial: NCT00992862
Drug: Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.
DrugBank: Moexipril (DB00691)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00410943
Drug: OROS Hydromorphone HCI SR (slow release)
RxNorm normalized name: Slow-Fe
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05120076
Drug: Dexamethasone 4 Mg/mL Injectable Solution
RxNorm normalized name: dexAMETHasone 4 mg/mL injectable solution
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: s. arm/group description
Trial: NCT04249427
Drug: Erenumab Prefilled Syringe
RxNorm normalized name: erenumab Prefilled Syringe
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 140mg Erenumab, pre-filled syringe given by subcutaneous injection
Trial: NCT05915871
Drug: Tegoprazan
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration
Trial: NCT05915871
Drug: Bismuth
RxNorm normalized name: Bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral administration
Trial: NCT05915871
Drug: Amoxicilli
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule for oral administration
Trial: NCT05483868
Drug: AU-011
RxNorm normalized name: Light-activated au-011
DrugBank: Belzupacap Sarotalocan (DB17317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of AU-011 intratumorally and intramurally
Trial: NCT05337085
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inj dexmedetomidine and inj midazolam given to 2 groups of participants and sedative effects of both drugs will be observed during surgery
Trial: NCT05337085
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam
Trial: NCT06349811
Drug: BL-M05D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT05468671
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil.
Trial: NCT05468671
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol is used to put you to sleep and keep you asleep during general anesthesia for surgery or other medical procedures.
Trial: NCT05468671
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium is a non-depolarizing neuromuscular blocker
Trial: NCT05468671
Drug: oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone is an opiate painkiller.
Trial: NCT05468671
Drug: Sugammadex Sodium
RxNorm normalized name: Sugammadex sodium
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sugammadex sodium is an organic sodium salt that is the octasodium salt of sugammadex. Used for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery
Trial: NCT05468671
Drug: Flumazenil
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil is used to reverse the effects of a benzodiazepine
Trial: NCT05516628
Drug: Adjuvant Atezolizumab-Bevacizumab Therapy
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patient receives adjuvant Atezolizumab plus Bevacizumab every 3-weekly for a year following resection of hepatocellular cancer tumour.
Trial: NCT05357846
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg, IV (in the vein) on day 1 and day 22
Trial: NCT05357846
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50mg/m2, IV (in the vein) on day 1,day 8,day 15 and day 22